ra-2

RA-2 is a pan-negative-gating modulator of KCa2/3 channels that acts by inhibiting EDH-type relaxation in coronary arteries.

Endothelin-2 (49-69), human (Human endothelin-2) is a 21-amino acid vasoactive peptide that binds to G-protein-linked transmembrane receptors, ET-RA and ET-RB.

Elsilimomab (B-E8), an IgG1 monoclonal antibody targeting interleukin-6 (IL-6), exhibits a dissociation constant (K D) of 22 pM and an inhibitory concentration (IC 50) of 1.4 nM. It is applicable in researching multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) [1] [2] [3].

Ginsenoside Ra2 is a natural product

Pegloxenatide, a glucagon-like peptide-1 receptor (GLP-1 RA) agonist, is utilized in type 2 diabetes research [1].

Baminercept (BG 9924), an IgG fusion protein targeting the lymphotoxin β receptor (LTβR-Ig), has potential applications in the study of various autoimmune diseases, such as primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) [1] [2].

AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; Kd= 2, 2, and 3 nM for RARα, β, and γ, respectively), exhibiting selectivity for RARs over retinoid X receptors (RXRs; Kd= >10,000 nM for human RXRα, β, and γ receptors). This compound effectively reverses cellular morphology changes and growth suppression induced by RAR agonists such as all-trans-RA, 13-cis-RA, and 9-cis-RA in ECE16-1 human endometrial ectocervical epithelial cells, particularly when used at a 10-fold molar excess. Furthermore, AGN 193109 downregulates the expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, indicating inhibition of retinoid action, specifically when co-administered with TTNPB but not as a standalone treatment. In vivo studies demonstrate teratogenic effects, including cleft palate, frontonasal dysplasia, and eye malformations in mouse fetuses following a single oral dose of 1 mg/kg.

CCR2-RA-[R] is a C-C chemokine receptor type 2 (CCR2) allosteric antagonist (IC50: 103 nM).

Remtolumab (ABT-122), a dual-variable domain immunoglobulin, neutralizes tumor necrosis factor α (TNFα) and IL-17A, demonstrating dual inhibition of both. This compound is utilized in rheumatoid arthritis (RA) research [1] [2].

Endothelin-2 (49-69), human (TFA) is a 21-amino acid vasoactive peptide that binds to ET-RA and ET-RB.

Bz-rA Phosphoramidite is used for ribonucleotides modification[1]. [1]. Elise Malek-Adamian, et al. 4'-C-Methoxy-2'-deoxy-2'-fluoro Modified Ribonucleotides Improve Metabolic Stability and Elicit Efficient RNAi-Mediated Gene Silencing. J Am Chem Soc. 2017 Oct 18;139(41):14542-14555.

IMMH001, also known as SYL930, is an orally active compound that exhibits potent selectivity as an agonist for the S1P1 receptor, which is the sphingosine-1-phosphate receptor 1. This compound effectively reduces the levels of various chemokines and proinflammatory cytokines, such as IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5. IMMH001 finds utility in research focused on rheumatoid arthritis (RA) [1] [2].

MCI, a chemical compound demonstrating significant anti-inflammatory effects, particularly in collagen-induced arthritis (CIA) models, modulates inflammation through macrophage reprogramming by enhancing ROS scavenging and promoting COX-2 downregulation. It effectively inhibits COX-2, exhibiting an IC50 of 1.23 μM. Additionally, MCI holds potential for research applications in rheumatoid arthritis (RA) [1].

BMS-681 is an orthosteric antagonist of chemokine receptor 2 (CCR2) that forms a ternary complex with CCR2 and its allosteric antagonist, CCR2-RA-[R]. Together, the complex inhibits chemokine binding with BVMS-681 in the orthosteric pocket and CCR2-RA-[R] in the intracellular allosteric G-protein binding site. When chemokine binding is inhibited, modulation responses implicated in several inflammatory and neurodegenerative diseases, including atherosclerosis, multiple sclerosis, asthma, neuropathic pain, diabetic nephropathy, and cancer can be controlled. This action occurs as the migration of monocytes, immature dendritic cells, and T-cell subpopulations towards endogenous CC chemokine ligands is mediated.

NF-κB/MAPK-IN-1 is a potent dual inhibitor of the NF-κB and MAPK pathways with potential anti-inflammatory activity, inhibition of NO production, and inhibition of LPS-induced activation of iNOS, COX-2, ERΚ and P38. NF-κB/MAPK-IN-1 is used for the prevention and treatment of rheumatoid arthritis (RA).

Briobacept (BR 3FC), a selective human monoclonal antibody, targets BLyS (BAFF) to induce B-cell apoptosis and is a recombinant glycoprotein comprising two BLyS receptor (BR3) molecules fused to the Fc domain of human IgG1. It has applications in the study of rheumatoid arthritis (RA) [1] [2].

CCP Peptide TFA, a synthetic cyclic citrullinated peptide, serves as a serological substrate for the detection of anti-CCP antibodies and is a highly specific target for autoantibodies associated with rheumatoid arthritis (RA) [1] [2].

Cabiralizumab (FPA 008), an anti-CSF1R monoclonal antibody (MAb), promotes T cell infiltration and boosts antitumor immune responses. It also prevents osteoclast activation, thereby inhibiting bone destruction, and is utilized in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab can be paired with Nivolumab in lung cancer studies [1] [2].

AFM-30a hydrochloride is a potent and highly selective inhibitor of protein arginine deiminase 2 (PAD2). aFM-30a hydrochloride binds to PAD2 (EC50: 9.5 μM) and also inhibits H3 guanylation (EC50: 0.4 μM). aFM-30a hydrochloride can be used to study certain cancers and various autoimmune diseases such as rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis.

Timapiprant sodium inhibits mast cell activation of Th2 lymphocytes and eosinophils. Timapiprant sodium is a potent and selective D prostanoid receptor 2 antagonist. Timapiprant sodium potently displaces [3H] PGD2 from human recombinant DP2 (Ki=13 nM), ra